| RAS Technology Holdings Limited (RTH) ORDINARY FULLY PAID |
Industrials |
$33 |
RTH Appendix 4G and Corporate Governance Statement
|
28 Aug 2025 9:37AM |
$0.950 |
$0.695 |
fallen by
26.84%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$490 |
Investor Presentation
|
28 Aug 2025 9:37AM |
$13.550 |
$9.710 |
fallen by
28.34%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company focused on developing and commercializing treatments for patients with unmet medical needs.
- The company's lead product, SCENESSE® (afamelanotide), is approved for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) in Europe, the US, and Australia.
- SCENESSE® has a unique mode of action as a melanocortin 1 receptor agonist, increasing melanin production and providing photoprotection.
- Clinuvel is pursuing expansion into new indications for SCENESSE®, including vitiligo, xeroderma pigmentosum (XP), and DNA repair disorders.
- The company is also developing a topical formulation (CUV9900) targeting repigmentation and DNA repair in skin diseases.
- Clinuvel is investing in the development of new melanocortin-based therapies for neurological, endocrinological, and cardiovascular indications.
- The company emphasizes long-term growth with a focus on innovation, geographical expansion, and operational excellence.
- Clinuvel maintains a strong financial position, with positive operating cash flow, no debt, and cash reserves to support ongoing R&D and commercial activities.
- Recent milestones include further market penetration in EPP, progress in clinical trials for vitiligo and XP, and an expanding global patient base.
- Clinuvel remains committed to delivering value for shareholders through scientific advancement, commercial execution, and prudent financial management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cromwell Property Group (CMW) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,152 |
FY25 ESG Report
|
28 Aug 2025 9:37AM |
$0.430 |
$0.440 |
risen by
2.33%
|
|
| Katana Capital Limited (KAT) ORDINARY FULLY PAID |
Financials |
$45 |
Notification of cessation of securities - KAT
|
28 Aug 2025 9:37AM |
$1.280 |
$1.410 |
risen by
10.16%
|
|
| EMvision Medical Devices Limited (EMV) ORDINARY FULLY PAID |
Health Care |
$159 |
Appendix 4E & Annual Report to 30 June 2025
|
28 Aug 2025 9:37AM |
$1.900 |
$1.710 |
fallen by
10%
|
|
EMV - Price-sensitive ASX Announcement
Full Release
Key Points
- EMvision Medical Devices Limited focuses on developing and commercializing portable brain imaging devices, primarily for stroke care.
- The company achieved significant milestones in product development and clinical trials during the year.
- Ongoing clinical studies are validating the effectiveness of EMvision’s brain scanner for rapid stroke assessment.
- Strategic partnerships and collaborations were advanced during the reporting period.
- The company reported key financial metrics, including revenue, profits/losses, and R&D expenditure.
- Corporate governance practices and risk management processes were reviewed and updated.
- The intellectual property portfolio, including patents, remains a key asset for the business.
- Regulatory planning and activities to support future product approvals progressed during the year.
- The financial statements and auditor’s reports reflect the company’s financial position as at 30 June 2025.
- EMvision is positioning itself for further commercialization and market entry based on the results achieved over the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$108 |
Paradigm Launches InvestorHub
|
28 Aug 2025 9:37AM |
$0.290 |
$0.180 |
fallen by
37.93%
|
|
| Nine Entertainment Co. Holdings Limited (NEC) ORDINARY FULLY PAID |
Communication Services |
$1,602 |
Appointment of Chief Financial Officer
|
28 Aug 2025 9:37AM |
$1.840 |
$1.010 |
fallen by
45.11%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$490 |
Corporate Governance Statement
|
28 Aug 2025 9:36AM |
$13.550 |
$9.710 |
fallen by
28.34%
|
|
| FOS Capital Ltd (FOS) ORDINARY FULLY PAID |
Industrials |
$10 |
FOS Capital 2025 Annual Report
|
28 Aug 2025 9:36AM |
$0.300 |
$0.140 |
fallen by
53.33%
|
|
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$3,751 |
Application for quotation of securities - LTR
|
28 Aug 2025 9:36AM |
$0.920 |
$1.180 |
risen by
28.26%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$490 |
Appendix 4G
|
28 Aug 2025 9:36AM |
$13.550 |
$9.710 |
fallen by
28.34%
|
|
| Technology One Limited (TNE) ORDINARY FULLY PAID |
Information Technology |
$10,888 |
Director Appointment/Resignation
|
28 Aug 2025 9:36AM |
$40.190 |
$33.260 |
fallen by
17.24%
|
|
| Amaero Ltd (3DA) CHESS DEPOSITARY INTERESTS 40:1 |
Industrials |
$219 |
Change in substantial holding - Pegasus
|
28 Aug 2025 9:36AM |
$0.370 |
$0.230 |
fallen by
37.84%
|
|
| VGI Partners Global Investments Limited (VG1) ORDINARY FULLY PAID |
Financials |
- |
Update - Notification of buy-back - VG1
|
28 Aug 2025 9:36AM |
$1.845 |
$1.950 |
risen by
5.69%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$490 |
Dividend/Distribution - CUV
|
28 Aug 2025 9:36AM |
$13.550 |
$9.710 |
fallen by
28.34%
|
|
| Horizon Oil Limited (HZN) ORDINARY FULLY PAID |
Energy |
$390 |
Appendix 4E and FY25 Annual Report to Shareholders
|
28 Aug 2025 9:35AM |
$0.210 |
$0.220 |
risen by
4.76%
|
|
HZN - Price-sensitive ASX Announcement
Full Release
Key Points
- Horizon Oil Limited (HZN) released its Appendix 4E and FY25 Annual Report to Shareholders.
- The report highlights HZN’s operational and financial performance for the fiscal year ended 30 June 2025.
- HZN operates primarily in Papua New Guinea and China, focusing on oil and gas exploration, development, and production.
- The company reported strong production from its core assets, particularly the Maari and Beibu Gulf projects.
- HZN’s financial position remains robust with solid cash flow generation and effective cost management.
- The company achieved significant milestones in asset development, including drilling success and field optimization.
- HZN’s board declared a dividend to shareholders, reflecting confidence in ongoing cash flow and operational stability.
- The report discusses risks and opportunities, including market fluctuations, geopolitical factors, and environmental considerations.
- HZN maintains a commitment to sustainability, safety, and corporate governance best practices.
- The outlook for FY26 remains positive, with the company targeting further production efficiencies and asset growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$367 |
Update - Notification of buy-back - RG8
|
28 Aug 2025 9:35AM |
$2.050 |
$2.610 |
risen by
27.32%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$490 |
CLINUVEL delivers ninth consecutive revenues growth & profit
|
28 Aug 2025 9:35AM |
$13.550 |
$9.710 |
fallen by
28.34%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel achieved its ninth consecutive year of revenue growth and profitability.
- Record revenues were primarily driven by increased global usage of SCENESSE® for EPP.
- Strong cash reserves support investment in R&D and commercial expansion.
- Clinuvel operates as a vertically integrated biopharmaceutical company with a diversified portfolio.
- The company’s pipeline includes melanocortin analogues for new indications beyond EPP.
- Ongoing clinical trials and research are targeting both rare and broader population disorders.
- Management reaffirmed a strategy of sustainable growth with continued financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sequoia Financial Group Ltd (SEQ) ORDINARY FULLY PAID |
Financials |
$15 |
Investor Presentation
|
28 Aug 2025 9:35AM |
$0.300 |
$0.125 |
fallen by
58.33%
|
|
SEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Sequoia Financial Group Ltd delivers a comprehensive suite of financial services, including wealth management, corporate trustee services, and professional services.
- The company’s strategy emphasizes growth through both organic initiatives and targeted acquisitions.
- Financial performance for the first half of FY24 demonstrates solid recurring revenue and disciplined cost management.
- Integration of recently acquired businesses is a priority, with expected synergies and operational efficiencies.
- Sequoia maintains a strong balance sheet, providing flexibility for future investments and acquisitions.
- Management is focused on improving margins, increasing shareholder value, and supporting sustainable long-term growth.
- The group’s diversified business model reduces reliance on any single revenue stream.
- Market positioning is reinforced by a national footprint, experienced management team, and a fully integrated platform.
- Ongoing investment in technology and compliance aims to enhance service delivery and regulatory outcomes.
- A robust pipeline of acquisition opportunities is expected to support continued expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lachlan Star Limited (LSA) ORDINARY FULLY PAID |
Materials |
$46 |
Proposed issue of securities - LSA
|
28 Aug 2025 9:35AM |
$0.057 |
$0.125 |
risen by
119.30%
|
|
| Lachlan Star Limited (LSA) ORDINARY FULLY PAID |
Materials |
$46 |
$2.16m Capital raising to accelerate drill testing
|
28 Aug 2025 9:35AM |
$0.057 |
$0.125 |
risen by
119.30%
|
|
LSA - Price-sensitive ASX Announcement
Full Release
Key Points
- Lachlan Star Limited (LSA) announces $2.16m capital raising.
- Funds will accelerate drill testing at the Koojan Copper-Gold Project in Western Australia.
- Drilling will target high-priority geophysical and geochemical anomalies.
- Recent exploration has revealed multiple high-potential targets at the project.
- The capital raise will expedite drilling and sampling programs.
- New shares will be issued under the placement, supported by both existing and new investors.
- The initiative aims to unlock project value and advance exploration for shareholders' benefit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$22 |
Excellent Grade Intersections at Down Under REE Project
|
28 Aug 2025 9:35AM |
$0.063 |
$0.071 |
risen by
12.70%
|
|
GMN - Price-sensitive ASX Announcement
Full Release
Key Points
- Gold Mountain Limited (GMN) reported significant drill results from the Down Under rare earth element (REE) project in Western Australia.
- Excellent grade intersections were achieved from the reconnaissance aircore drilling program, with high concentrations of total rare earth oxides (TREO) including valuable magnet rare earths.
- Key drillholes returned thick mineralized intervals, including up to 44 meters at 1,634 ppm TREO, with very high heavy rare earth and magnet REE content.
- The Down Under project is strategically located in the Yilgarn Craton, an area recognized for its potential for clay-hosted REE deposits.
- Geological analysis indicates that REE mineralization is hosted in both saprolite and saprock zones, with clay zones showing particularly strong enrichment.
- Early metallurgical testing demonstrates promising leachability of the REE mineralization using standard ammonium sulfate methods.
- The company is planning further drilling, detailed metallurgical testwork, and resource estimation to advance the project.
- The results confirm the Down Under project's potential as a significant new source of rare earths in Western Australia, aligning with global demand for critical minerals.
- GMN intends to continue systematic exploration and engage with government and community stakeholders as the project progresses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sequoia Financial Group Ltd (SEQ) ORDINARY FULLY PAID |
Financials |
$15 |
FY25 Financial Results
|
28 Aug 2025 9:35AM |
$0.300 |
$0.125 |
fallen by
58.33%
|
|
SEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Release of FY25 financial results with detailed revenue, cost, and profitability data.
- Discussion of key achievements and operational challenges faced during the fiscal year.
- Emphasis on strategic initiatives for growth, including technological investment and service expansion.
- Overview of risk management improvements and responses to market and regulatory conditions.
- Commitment to sustainable growth, innovation, and enhancing shareholder value.
- Focus on strengthening client relationships and adapting to evolving market dynamics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RAS Technology Holdings Limited (RTH) ORDINARY FULLY PAID |
Industrials |
$33 |
RTH FY25 Results Presentation
|
28 Aug 2025 9:35AM |
$0.950 |
$0.695 |
fallen by
26.84%
|
|
RTH - Price-sensitive ASX Announcement
Full Release
Key Points
- Summarizes financial results and key operational highlights for FY25.
- Details revenue growth, operating expenses, EBITDA, and profit after tax.
- Describes business segments and market positioning within the racing and wagering technology sector.
- Outlines strategic initiatives including technology investment and international expansion.
- Discusses new partnerships, product innovation, and customer acquisition efforts.
- Addresses challenges such as regulatory impacts and market competition.
- Highlights focus on cost efficiencies and sustainable long-term growth.
- Emphasizes commitment to shareholder value and market leadership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| S2 Resources Limited (S2R) ORDINARY FULLY PAID |
Materials |
$38 |
Drill Testing of Multi-element Soil Anomaly, West Murchison
|
28 Aug 2025 9:34AM |
$0.120 |
$0.072 |
fallen by
40%
|
|
S2R - Price-sensitive ASX Announcement
Full Release
Key Points
- S2 Resources Limited has started drill testing at West Murchison in Western Australia.
- The drill program targets a strong multi-element soil anomaly (copper, gold, arsenic).
- Soil geochemical surveys identified a significant anomaly with potential for mineralization.
- The initial drilling comprises approximately 2,500 meters of reverse circulation (RC) drilling.
- The aim is to test the core of the anomaly for economic mineralization.
- Drilling results will guide future exploration programs.
- The project is strategically located and represents an opportunity for new discovery.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
